LENZ Therapeutics, Inc. - Common Stock, par value $0.00001 per share (LENZ)

CUSIP: 52635N103

Q4 2025 13F Holders as of 31 Dec 2025

Holder snapshot 7 signals
Share change
+5,451,973
Put/Call ratio
380%
SEC-reported price per share
$16.00
Number of holders
161
Value change
-$86,155,656
Number of buys
99
Open additional details 1 more signal available
Number of sells
88
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
31,441,412

Security key

52635N103

Report period

Q4 2025

Institutions

161

Top holders

10

Ownership snapshot

Top reported holders of LENZ - LENZ Therapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G 13F 3/4/5 Lead comparable stake: 14% 13D/G row: RA CAPITAL MANAGEMENT, L.P. Showing 1-6 of 15 holder rows.

Quick read

RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 14%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership Top 5
RA CAPITAL MANAGEMENT, L.P. 14%
FMR LLC 12%
Point72 Asset Management, L.P. 4.8%
Paradigm Biocapital Advisors LP 3.8%
Versant Venture Capital VI, L.P. 3.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
RA CAPITAL MANAGEMENT, L.P.
13D/G 13F
Company
14%
$198,668,637
4,265,106 shares
+$209,610 05 Nov 2025
FMR LLC
13D/G 13F
Company
12%
$59,243,480
3,702,718 shares
-$9,208,416 31 Dec 2025
Point72 Asset Management, L.P.
13D/G 13F
Steven A. Cohen · Company
4.8%
$63,244,042
1,357,751 shares
$0 30 Sep 2025
Paradigm Biocapital Advisors LP
13D/G 13F
Company
3.8%
$50,001,813
1,073,461 shares
-$16,133,961 30 Sep 2025
Versant Venture Capital VI, L.P.
3/4/5 13D/G
10%+ Owner
3.4%
from 13D/G
$85,316,256
1,814,726 shares
-$33,745,537 30 Sep 2025
Alpha Wave Global, LP
13F
Company
13F
11%
$168,256,788
3,612,211 shares
30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
161
Shares
35,070,612
Rows available
161
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
166
Q4 2025 holders
161
Holder diff
-5
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .